Advancing the Next Generation of
Mental Health Therapeutics

PsyRx is a CNS pharmaceutical development company advancing innovative ibogaine-based therapies for depression, PTSD, and other neuropsychiatric disorders.
Our Science
PsyRx is developing a novel ibogaine-based therapeutic approach designed to enhance neuroplasticity and improve outcomes for patients with depression and related neuropsychiatric disorders.
Once-daily oral dosage form
Administered without clinical supervision
Designed for efficacy with minimal side effects
No interruption to patients' daily lives

Transforming Mental Health Treatment

PsyRx is pursuing a differentiated pharmaceutical development strategy based on low-dose ibogaine, designed to explore therapeutic benefits while supporting safety, tolerability, and scalability within a regulated pharmaceutical framework.
Founded in 2019, PsyRx is focused on developing differentiated therapies for major unmet needs in mental health. Unlike clinic-based psychedelic treatment models, PsyRx is pursuing a pharmaceutical pathway designed to create scalable, prescription-based therapeutic products.
Learn More

Unleashing the Therapeutic
potential of Ibogaine

PsyRx at a Glance

Founded in 2019, PsyRx is a publicly traded pharmaceutical development company advancing a proprietary ibogaine-based platform for neuropsychiatric disorders.

  • Depression affects approximately 280 million people worldwide
  • Two development programs: PSX-001 (Clinical Readiness) and PSX-002 (Discovery / Preclinical)
  • PCT patent portfolio protecting proprietary technology in Israel and the U.S.
  • International scientific collaborations and a defined U.S. expansion strategy
PTSD & Veterans Initiative

PsyRx is exploring future research and development opportunities focused on post-traumatic stress disorder (PTSD), trauma-related conditions, and veterans’ mental health.

As part of its long-term strategic vision, the Company is evaluating potential scientific collaborations, academic partnerships, and funding opportunities that may support the future development of innovative therapies for trauma-related disorders.

  • Post-Traumatic Stress Disorder (PTSD)
  • Trauma-related mental health conditions
  • Veterans’ mental health
  • Neuroplasticity research
Pipeline

PsyRx is developing a pipeline of innovative ibogaine-based therapies designed to address significant unmet needs in neuropsychiatric disorders.

PSX-001 — Major Depressive Disorder (MDD) — Clinical Readiness

PSX-002 — PTSD & Trauma-Related Disorders — Discovery / Preclinical

Additional neuropsychiatric and CNS indications are under evaluation.

Intellectual Property Strategy

Intellectual property is a core component of PsyRx’s long-term development strategy, supporting sustainable competitive advantages in the neuropsychiatric therapeutics market.

  • Protecting scientific innovation
  • Supporting long-term shareholder value
  • Strengthening commercial positioning
  • Creating barriers to market entry

The Company is also pursuing international protection and evaluating regulatory exclusivity opportunities as part of its global development strategy.

Ecosystem & Partners

Hebrew University of Jerusalem — Academic Research

Formulex — Drug Development

Pharmaseed — Preclinical Research

HBI Biotech Sciences — Collaboration

PsyRx continues to evaluate future collaborations with academic institutions, medical centers, government-funded programs, and international research organizations.

Key Objectives

Faster therapeutic onset
Improved response in difficult-to-treat patient populations
Reduced side-effect burden
Improved patient adherence
PsyRx is developing proprietary ibogaine-based therapeutic approaches designed to address limitations associated with current treatment options.
Clinical advantage: faster onset of action, improved mood outcomes, and a reduced side-effect profile, supporting lower patient burden and treatment cost
The Company has established an intellectual property portfolio designed to support long-term value creation and future commercialization opportunities.
Regulatory advantage: a development pathway designed to support an accelerated regulatory approval process
Learn More

Roadmap
Advancing Toward Clinical Development

1
Stage 1 — Discovery &
Platform Development
Company founded, intellectual property strategy established, Scientific Advisory Board formed, and the preclinical research program initiated.
2
Stage 2 — Preclinical
Development
GLP toxicology studies and pharmacokinetic (PK) studies completed, manufacturing process development advanced, and a technical development package prepared.
3
Stage 3 — Clinical
Readiness
GMP API supply, animal efficacy studies, clinical product manufacturing, stability program, and regulatory documentation — the Company's current phase of development.
4
Stage 4 — Clinical
Development
Regulatory submission, clinical site initiation, first patient enrollment, and first patient dosed.
5
Stage 5 — Clinical
Proof of Concept
Safety evaluation, efficacy assessment, and clinical data generation supporting continued clinical development.
6
Stage 6 — Strategic
Growth
FDA engagement activities, strategic partnerships, licensing opportunities, and international expansion.

Science & Technology

Depression and trauma-related disorders remain among the most significant public health challenges globally. Although current antidepressants have helped millions of patients, many continue to experience delayed onset of action, partial treatment response, treatment resistance, relapse, and side effects limiting adherence.

PsyRx is investigating novel ibogaine-based therapeutic approaches that may influence neuroplasticity, neural adaptation, and mood-related biological pathways. Our programs are developed according to internationally recognized pharmaceutical standards, including GMP manufacturing, regulatory compliance, controlled clinical studies, and quality-by-design principles. Platform characteristics

Leveraging existing know-how and technology

Controlled, GMP-aligned processes
Reproducible quality and yield
Scalable manufacturing suitable for late-stage development
Cost-efficient production design

Management

Itay Hecht
Chief Executive Officer & Co-Founder
Biopharma executive with experience in company formation, public markets, strategic business development, and healthcare innovation. Led the IPO of Israel's first publicly traded medical cannabis company and has extensive experience in building and advancing emerging life-science ventures.
Prof. Itamar Grotto, MD, MPH, PhD
Chairman of the Board
Professor of Epidemiology and Public Health. Former Associate Director General of the Israeli Ministry of Health and former Member of the Executive Board of the World Health Organization (WHO). Brings extensive experience in healthcare policy, public health, and regulatory affairs.
Kobi Buxdorf, PhD
Chief Technology Officer & Co-Founder
Entrepreneur, founder of Cannadorf and Tincoil, Co-founder of Wilk (TLV:WILK). Over 10 years of academic and industrial research and management experience in microbiology, molecular biology, plant sciences, diagnostics and medical devices. Extensive background in regulation, business development, and commercialization of basic science.

Scientific Advisory Board

Prof. Maggie Levy, Ph.D
Scientific Advisor
Prof. Aaron Ciechanover, MD, DSc
Scientific Advisor
Prof. Itzhak Haviv, PhD
Strategic Scientific Advisor
Dr. Susan Alpert
Strategic Advisor
Dr. Nadav Goldental
Scientific Advisor
Prof. Moshe Kotler, MD, MHA
Scientific Advisor

Partner With
PsyRx

PsyRx welcomes discussions with pharmaceutical companies, academic institutions, clinical investigators, strategic investors, veterans organizations, and government funding agencies.
Get In Touch





    Skip to content